Clinical Trials

Title   RIN-PH-201 A Multicenter, Randomized, Double-blinded, Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
Description   This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately 120 clinical trial centers. The treatment phase of the study will last approximately 16 weeks. Patients who complete all required assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).
IRB Number   18-037
Treatment   Pulmonary Arterial Hypertension
Status   Active
Start Date   02/19/2018
Principal Name   Karen Fagan M.D.
Contact Name   Erica Sutherland

Email Newsletters

Connect With Us